PEOPLE ON THE MOVE
Vium hires new CSO David Hutto
California-based Vium Inc. has appointed David Hutto as its new Chief Scientific Officer.
Vium is developing a digital platform for preclinical testing of drug targets as an alternative to animal models. Current indication areas include biologic and small molecule therapeutics for autoimmune diseases, rare diseases, liver failure and cancer.
Formerly the CSO of Charles Rivers Laboratories, Hutto will help the firm develop its strategic growth plan. Previous roles have included R&D roles in Drug Safety and comparative pathology at Millennium Pharmaceuticals, Eisai US and Biogen.
